{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:16:23Z","timestamp":1784330183758,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaccao.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T14:02:46Z","timestamp":1687874566000},"page":"520-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7429-4724","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Moledina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mallity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jaccao.2023.04.003_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.jaccao.2023.04.003_bib2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jaccao.2023.04.003_bib3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3324\/haematol.2018.197814","article-title":"Arterial thrombosis and cancer: the neglected side of the coin of Trousseau syndrome","volume":"103","author":"De Stefano","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jaccao.2023.04.003_bib4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"41","key":"10.1016\/j.jaccao.2023.04.003_bib5","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.18632\/oncotarget.24599","article-title":"Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review","volume":"10","author":"Bai","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaccao.2023.04.003_bib6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.thromres.2021.11.009","article-title":"Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4\/6 inhibitors: a systematic review and meta-analysis","volume":"208","author":"Bolzacchini","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaccao.2023.04.003_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2019.10.004","article-title":"Frequency of arterial thromboembolism in populations with malignancies: a systematic review","volume":"184","author":"Yu","year":"2019","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.jaccao.2023.04.003_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100338","article-title":"Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management","volume":"7","author":"Vallerio","year":"2022","journal-title":"ESMO Open"},{"issue":"23","key":"10.1016\/j.jaccao.2023.04.003_bib9","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/jnci\/djs435","article-title":"Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis","volume":"104","author":"Proverbs-Singh","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jaccao.2023.04.003_bib10","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2023.04.003_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9343(89)80604-7","article-title":"Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study","volume":"87","author":"Wall","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.jaccao.2023.04.003_bib12","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Rutjes","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"40","key":"10.1016\/j.jaccao.2023.04.003_bib13","doi-asserted-by":"crossref","first-page":"E1551","DOI":"10.1503\/cmaj.210523","article-title":"Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer","volume":"193","author":"Kimpton","year":"2021","journal-title":"CMAJ"},{"issue":"12","key":"10.1016\/j.jaccao.2023.04.003_bib14","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/jth.14613","article-title":"Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis","volume":"17","author":"Li","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jaccao.2023.04.003_bib15","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1002\/onco.13596","article-title":"Update on guidelines for the management of cancer-associated thrombosis","volume":"26","author":"Streiff","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jaccao.2023.04.003_bib16","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jaccao.2023.04.003_bib17","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1055\/s-0040-1712143","article-title":"Assessing full benefit of rivaroxaban prophylaxis in high-risk ambulatory patients with cancer: thromboembolic events in the randomized CASSINI trial","volume":"4","author":"Khorana","year":"2020","journal-title":"TH Open"},{"issue":"9","key":"10.1016\/j.jaccao.2023.04.003_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jaccao.2023.04.003_bib19","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A\u00a0meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"20","key":"10.1016\/j.jaccao.2023.04.003_bib21","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jaccao.2023.04.003_bib22","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","article-title":"An updated definition of stroke for the 21st century: a statement for health care professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Sacco","year":"2013","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.jaccao.2023.04.003_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jaccao.2023.04.003_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2021.02.012","article-title":"A\u00a0proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies","volume":"135","author":"Xu","year":"2021","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jaccao.2023.04.003_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.jaccao.2023.04.003_bib27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2023.04.003_bib28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III Trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.jaccao.2023.04.003_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jaccao.2023.04.003_bib30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Ann Oncol"},{"issue":"8902","key":"10.1016\/j.jaccao.2023.04.003_bib31","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jaccao.2023.04.003_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jaccao.2023.04.003_bib33","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jaccao.2023.04.003_bib34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jaccao.2023.04.003_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9663","key":"10.1016\/j.jaccao.2023.04.003_bib36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(09)60205-1","article-title":"Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial","volume":"373","author":"Young","year":"2009","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jaccao.2023.04.003_bib37","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"van Doormaal","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaccao.2023.04.003_bib38","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01220-2018","article-title":"Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial","volume":"52","author":"Meyer","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jaccao.2023.04.003_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00280-013-2169-y","article-title":"Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study","volume":"72","author":"Lavau-Denes","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.jaccao.2023.04.003_bib40","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.jaccao.2023.04.003_bib41","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jaccao.2023.04.003_bib42","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2023.04.003_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.966190","article-title":"Incidence of stroke in the first year after diagnosis of cancer-a systematic review and meta-analysis","volume":"13","author":"Lun","year":"2022","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.jaccao.2023.04.003_bib44","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"Van Es","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jaccao.2023.04.003_bib45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccao.2023.04.003_bib46","first-page":"CD003464","article-title":"Antiplatelet and anticoagulation for patients with prosthetic heart valves","volume":"7","author":"Massel","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.jaccao.2023.04.003_bib47","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ene.14172","article-title":"Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial","volume":"27","author":"Martinez-Majander","year":"2020","journal-title":"Eur J Neurol"},{"issue":"23","key":"10.1016\/j.jaccao.2023.04.003_bib48","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jaccao.2023.04.003_bib49","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jaccao.2023.04.003_bib50","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jaccao.2023.04.003_bib51","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"Van Es","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jaccao.2023.04.003_bib52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12955-017-0621-0","article-title":"Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach","volume":"15","author":"Zhang","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"10.1016\/j.jaccao.2023.04.003_bib53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMe1113672","article-title":"Routine heparin for patients with cancer? One answer, more questions","volume":"366","author":"Akl","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jaccao.2023.04.003_bib54","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1016\/S2352-3026(20)30293-3","article-title":"Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis","volume":"7","author":"Sch\u00fcnemann","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jaccao.2023.04.003_bib55","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1055\/s-0040-1709712","article-title":"The efficacy and safety of low molecular weight heparin administration to improve survival of cancer patients: a systematic review and meta-analysis","volume":"120","author":"Montroy","year":"2020","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.jaccao.2023.04.003_bib56","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/jth.12666","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials: reply","volume":"12","author":"Sanford","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jaccao.2023.04.003_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071375","article-title":"Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial","volume":"378","author":"Auer","year":"2022","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jaccao.2023.04.003_bib58","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/ijgc-2021-002786","article-title":"Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A\/MaNGO-OV2A trial","volume":"31","author":"Di Liello","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.jaccao.2023.04.003_bib59","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/jth.15175","article-title":"Discordant reporting of VTE in pancreatic cancer: a systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7323","key":"10.1016\/j.jaccao.2023.04.003_bib60","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study","volume":"323","author":"Devereaux","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jaccao.2023.04.003_bib61","doi-asserted-by":"crossref","first-page":"n1205","DOI":"10.1136\/bmj.n1205","article-title":"Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial","volume":"373","author":"Kovacs","year":"2021","journal-title":"BMJ"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:56:32Z","timestamp":1762973792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087323001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2666087323001205"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.04.003","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}